Oncology

266 Items

All Items

Whole-exome sequencing reveals rare genetic variations in ovarian granulosa cell tumor

Seungyeon Kim, Songmi Kim, Seyoung Mun, Yongsik Kwak, Kwang-Sun Suh, Song-Yi Choi, Kyudong Han

403-411
WFDC3 identified as a prognostic and immune biomarker in pancreatic cancer

Bohan Liu, Xuqing Shi, Tianqi Liu, Huanwen Wu, Zhiyong Liang

2447–2465
WD-3 inhibits the proliferation of breast cancer cells by regulating the glycolytic pathway

Xiaodan Zhu, Lu Zhao, Jianliang You, Yiqun Ni, Zhipeng Wei, Qing Xue, Chunhui Jin

226-235
VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating UBR5 mRNA and m6A levels

Chunyu Zhu, Yameng Cheng, Yao Yu, Yanning Zhang, Guiyun Ren

1244–1257
VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma

Lidija Todorović, Boban Stanojević

26-36
Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774

Maciej Zalewski, Julita Kulbacka, Jolanta Saczko, Małgorzata Drag-Zalesinska, Anna Choromanska

234-241
Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer

Wei Zhang, Lunhua Huang, Xinyang Lu, Kecheng Wang, Xiaofei Ning, Zhiqiang Liu

164-171
UPP1 and AHSA1 as emerging biomarkers and targets in pancreatic cancer: A proteomic approach

Kongfan Zhu, Hua Hu, Yuanfa Tao, Zhijian Yang, Hanjun Li

2466–2480
Unknown primary adenocarcinomas: a single-center experience

Sernaz Uzunoglu, Bulent Erdogan, Hilmi Kodaz, Ahmet Cinkaya, Esma Turkmen, Ilhan Hacibekiroglu, Ali Sari, Alaattin Ozen, Ufuk Usta, Irfan Cicin

292-297
Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy

Semir Vranic, Zoran Gatalica

673–675
Tumor suppressor maspin as a modulator of host immune response to cancer

Sijana H. Dzinic, Maria M. Bernardo, Daniel S.M. Oliveira, Marian Wahba, Wael Sakr, Shijie Sheng

1-6
Tumor suppressive function of microRNA-192 in acute lymphoblastic leukemia

Mahtab Sayadi, Soheila Ajdary, Fatemeh Nadali, Shahrbano Rostami, Mahdi Edalati Fahtabad

248-254
Tumor Suppresser Gene p53 Expression in Premalignant Lesions and Gastric Carcinoma - Prognostic Value

Zora Vukobrat-Bijedić, Svjetlana Radović, Azra Husić-Selimović, Srđan Gornjaković

7-10
Tumor hypoxia: Classification, detection, and its critical role in cancer progression

Yan Zhao, Bing Zhong, Jing-Yi Cao, Qian Wang, Jie Liang, Ke Lu, Sheng-Ming Lu

1672–1690
Tumor glucose reprogramming suppresses cuproptosis: A review

Xiao-Hang Song, Yi-Hang Ding, Jing-Song Chen

251–261
Treatment of Severe Cancer Pain by Transdermal Fentanyl

Dženita Ljuca, Samir Husić

158-164
Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study

Aline Rangel-Pozzo, Tinuccia Dettori, Daniela Virginia Frau, Federica Etzi, John Gartner, Garbor Fisher, Roberta Vanni, Sabine Mai, Paola Caria

481-487
The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology

Muhammed Erkam Sencar, Sema Hepsen, Murat Çalapkulu, Hayri Bostan, Davut Sakiz, Ilknur Ozturk Unsal, Hakan Duger, Muhammed Kizilgul, Bekir Ucan, Tugba Taskin Turkmenoglu, Mustafa Ozbek, Erman Cakal

118-123
The value of elastography strain rate ratio in benign and malignant BI-RADS-US 3-4 breast masses

Xinping Li, Weixu Sun, Hongbiao Zhang

625–632
The value of 18F-FDG PET/CT imaging in breast cancer staging

Ulkem Yararbas, Neslihan Cetin Avci, Levent Yeniay, Aziz Murat Argon

72-79

1-20 of 266 Next